Geron Corporation (GERN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Foster City, CA, United States. The current CEO is Harout Semerjian.
GERN has IPO date of 1996-07-31, 229 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $1.08B.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
